CN110536888A - 一种苯并哌啶类衍生物的盐、其晶型及盐、其晶型的制备方法 - Google Patents

一种苯并哌啶类衍生物的盐、其晶型及盐、其晶型的制备方法 Download PDF

Info

Publication number
CN110536888A
CN110536888A CN201880026325.3A CN201880026325A CN110536888A CN 110536888 A CN110536888 A CN 110536888A CN 201880026325 A CN201880026325 A CN 201880026325A CN 110536888 A CN110536888 A CN 110536888A
Authority
CN
China
Prior art keywords
solvent
solvents
water
salt
mixed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880026325.3A
Other languages
English (en)
Other versions
CN110536888B (zh
Inventor
尤凌峰
邵成
冯君
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN110536888A publication Critical patent/CN110536888A/zh
Application granted granted Critical
Publication of CN110536888B publication Critical patent/CN110536888B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

公开了一种苯并哌啶类衍生物的盐、其晶型及盐、其晶型的制备方法。具体地，公开了(E)‑3‑(4‑((1R,3R)‑2‑(4‑环丙基苯基)‑6‑(1‑乙基‑1H‑吡唑‑4‑基)‑3‑甲基‑1,2,3,4‑四氢异喹啉‑1‑基)苯基)丙烯酸的L‑赖氨酸盐、其I晶型及其制备方法。式(I)化合物、其I晶型具备良好的稳定性、工艺简单易于操作，可更好地用于临床治疗。

Description

PCT国内申请，说明书已公开。

Claims (12)

  1. PCT国内申请，权利要求书已公开。
CN201880026325.3A 2017-06-20 2018-06-19 一种苯并哌啶类衍生物的盐、其晶型及盐、其晶型的制备方法 Active CN110536888B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017104668453 2017-06-20
CN201710466845 2017-06-20
PCT/CN2018/091781 WO2018233591A1 (zh) 2017-06-20 2018-06-19 一种苯并哌啶类衍生物的盐、其晶型及盐、其晶型的制备方法

Publications (2)

Publication Number Publication Date
CN110536888A true CN110536888A (zh) 2019-12-03
CN110536888B CN110536888B (zh) 2022-07-26

Family

ID=64737482

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880026325.3A Active CN110536888B (zh) 2017-06-20 2018-06-19 一种苯并哌啶类衍生物的盐、其晶型及盐、其晶型的制备方法

Country Status (3)

Country Link
CN (1) CN110536888B (zh)
TW (1) TWI666207B (zh)
WO (1) WO2018233591A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023221978A1 (zh) * 2022-05-17 2023-11-23 北京诺康达医药科技股份有限公司 一种多赖氨酸盐及其制备方法和纯化方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015024111A1 (en) * 2013-08-21 2015-02-26 Universite Laval Compounds for the treatment of hormone-dependent diseases
WO2015092634A1 (en) * 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
CN105229004A (zh) * 2013-05-28 2016-01-06 阿斯利康(瑞典)有限公司 化合物
CN107428721A (zh) * 2015-12-22 2017-12-01 江苏恒瑞医药股份有限公司 苯并哌啶类衍生物、其制备方法及其在医药上的应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105229004A (zh) * 2013-05-28 2016-01-06 阿斯利康(瑞典)有限公司 化合物
WO2015024111A1 (en) * 2013-08-21 2015-02-26 Universite Laval Compounds for the treatment of hormone-dependent diseases
US20160200685A1 (en) * 2013-08-21 2016-07-14 UNIVERSITé LAVAL Substituted 1,2,3,4-tetrahydroisoquinoline derivatives for the treatment of hormone-dependent diseases
WO2015092634A1 (en) * 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
CN107428721A (zh) * 2015-12-22 2017-12-01 江苏恒瑞医药股份有限公司 苯并哌啶类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
WO2018233591A1 (zh) 2018-12-27
TWI666207B (zh) 2019-07-21
CN110536888B (zh) 2022-07-26
TW201904954A (zh) 2019-02-01

Similar Documents

Publication Publication Date Title
EP3248983B1 (en) Crystal form a of obeticholic acid and preparation method therefor
JP7153030B6 (ja) オピオイド受容体（ｍｏｒ）アゴニスト塩、そのフマレート塩ｉ結晶形態、およびその製造方法
CN108727347B (zh) 一种阿片样物质受体(mor)激动剂的晶型及其制备方法
KR102516745B1 (ko) Ｃ-Ｍｅｔ 억제제의 결정질 유리 염기 또는 이의 결정질 산 염, 및 이들의 제조방법 및 용도
TW202220962A (zh) 選擇性NaV抑制劑的結晶形式及其製備方法
CN109937200B (zh) 一种苯并呋喃类衍生物游离碱的晶型及制备方法
US9884856B2 (en) Crystal form of Dabrafenib mesylate and preparation method thereof
CN108884099B (zh) 一种咪唑并异吲哚类衍生物的游离碱的结晶形式及其制备方法
CN110536888B (zh) 一种苯并哌啶类衍生物的盐、其晶型及盐、其晶型的制备方法
CN113966332A (zh) Cdk9抑制剂的多晶型物及其制法和用途
CN111349076B (zh) 一种苯并哌啶类衍生物的l-赖氨酸盐的晶型及其制备方法
CN113631542B (zh) 一种芳香族化合物的固体形式及其制备方法
CN113840605B (zh) N-(5-((4-乙基哌嗪-1-基)甲基)吡啶-2-基)-5-氟-4-(3-异丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺盐酸盐的结晶形式及其用途
TWI745764B (zh) 一種鴉片類物質受體激動劑的結晶形式及製備方法
JP2022508864A (ja) チロシンキナーゼ阻害剤のマレイン酸塩の結晶形及びその調製方法
US20170166559A1 (en) Solid state forms of a pde10 inhibitor
WO2023131017A1 (zh) 一种稠环衍生物的晶型、其制备方法及其应用
TWI717859B (zh) 一種鴉片類物質受體激動劑的結晶形式及製備方法
RU2779119C2 (ru) Соль агониста опиоидного рецептора (mor), кристаллическая форма i его фумаратной соли и способ их получения
TW201904972A (zh) 一種咪唑并異吲哚類衍生物游離鹼的晶型及其製備方法
WO2019029477A1 (zh) 一种酪氨酸激酶抑制剂的二马来酸盐的晶型及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant